HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supply Side East In Brief

This article was originally published in The Tan Sheet

Executive Summary

Cargill glucosamine: Regenasure non-shellfish, non-animal derived glucosamine hydrochloride will be commercially available in June after Cargill's new Eddyville, Iowa plant begins manufacturing product, company says at Supply Side East in Secaucus, N.J. May 6. Cargill has dedicated $10 mil.-$15 mil. to production of the premium-priced ingredient, according to the firm. Initial trade ad for Regenasure broke in April issue of Nutraceuticals World. Ingredient is expected to be available to consumers through both pill/capsule and beverage form by the end of 2003...

You may also be interested in...



Nutrition 21 Diachrome, Zeramax Sales To Be Backed By Research Initiatives

Nutrition 21 plans to support the broad launch of its Diachrome chromium picolinate/biotin blend with a relatively large-scale clinical study, according to President and CEO Gail Montgomery

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128934

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel